Cerecor is a Baltimore-based biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric diseases. We are committed to the development of drugs that improve lives by applying our extensive knowledge and experience in central nervous system disorders. Cerecor is currently pursuing the development of two clinical Phase II-stage product candidates: CERC-301: An oral, NR2B specific, NMDA receptor antagonist targeting the adjunctive treatment of patients with MDD who are failing to achieve adequate response, and CERC-501: A potent and selective kappa opioid receptor (KOR) antagonist targeting the adjunctive treatment of MDD and substance use disorders. . Cerecor recently licensed CERC-611 (formerly  LY3130481) from Lilly.  CERC-611 is a potent and selective Transmembrane AMPA Receptor Regulatory Proteins (“TARP”)-γ8-dependent AMPA receptor antagonist being developed as an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy. In addition Cerecor is conducting preclinical testing of CERC-406, a brain penetrant COMT inhibitor with potential procognitive activity. Learn More


October 10, 2016

Cerecor to Present at the 15th Annual BIO Investor Forum in San Francisco on October 18th, 2016

Read More

September 26, 2016

Cerecor Announces Acquisition of TARP-γ8-AMPA  Receptor Antagonist (CERC-611) from Lilly

Read More